Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Trillium bowel drug given orphan status
Necrotizing enterocolitis (NEC) is a medical condition primarily seen in premature infants, where portions of the bowel undergo tissue death. “Orphan drug status provides TTI-1612 with up to
Necrotizing enterocolitis (NEC) is a medical condition primarily seen in premature infants, where portions of the bowel undergo tissue death. “Orphan drug status provides TTI-1612 with up to
The total potential value of the agreement was much greater than expected and is the largest ever secured by a biotech company, including the $2 billion deal between
GenVec believes the data may allow the company to implement modifications to the study that could potentially accelerate its conclusion and allow an earlier review by the FDA
HIV-associated lipodystrophy is characterized by major physical changes as well as lipid and carbohydrate disorders, conditions that can foster cardiovascular disease and type 2 diabetes. Patient discomfort with
The decision was taken following a significant imbalance in fluid retention in patients in the study. Speedel commented that fluid retention is not unusual in patients who have
The global trial program for isavuconazole focuses on patients with invasive candidiasis including candidemia and patients with aspergillosis. The program targets two very significant patient groups with high
The Albuferon phase III development program includes two trials to evaluate the efficacy, safety and impact on health-related quality of life of Albuferon in combination with ribavirin, versus
Phenoptin is for patients with phenylketonuria (PKU) who have elevated phenylalanine (Phe) levels. Preliminary data has suggested that Phenoptin has potential to produce significant reductions in blood Phe
Vernakalant hydrochloride is an investigational new drug for the acute conversion of atrial fibrillation. The two companies have submitted more information after the initial application was rejected. “This
The application is supported by data from two phase III clinical studies and three phase II studies in patients with pulmonary arterial hypertension (PAH) and Gilead is asking